NOACs: Safety and Efficacy

NOAC Hazard Ratios vs warfarin*
  Dabigatran Edoxaban# Rivaroxaban Apixaban
Major bleeding HR 0.93 HR 0.80 HR 1.03 HR 0.68
GI bleeding HR 1.50 HR 1.23 HR 1.58 HR 0.89
All CVA + Sys Embolism HR 0.65 HR 0.87 HR 0.88 HR 0.79
Ischemic CVA HR 0.75 HR 1.00 HR 0.99 HR 0.92
Hemorrhagic CVA HR 0.26 HR 0.54 HR 0.59 HR 0.51
HR < 1 less likely with the NOAC than warfarin
HR > 1 less likely with warfarin than the NOAC
HR = 1 no detected difference
*As published from the randomized controlled trials, RE-LY, ENGAGE AF-TIMI 48,
ROCKET-AF, and ARISTOTLE
#High dose group (60mg)